Phospholipid liposomes in depression: a double-blind study versus placebo.
Phospholipid liposomes (PL) are capable of stimulating the activity of dopamine (DA)-sensitive adenylate cyclase in mouse brain, and inducing a modification of the noradrenergic hypothalamic system in rat. Changes of prolactin and growth hormone secretion have been observed in humans given PL. A recent double-blind clinical study suggests that liposomes have a good antidepressive effect in depressive patients. 26 patients with depressive syndrome were included in a double-blind study; 13 patients were treated with clomipramine (CI) + placebo (P), and 13 with CI + PL. The dose of CI was 75 mg orally daily, that of PL was 200 mg by intravenous infusion in 500 ml isotonic saline solution daily. The symptomatology was evaluated on days 0, 7, 14, and 21 using the Hamilton Rating Scale. The results of this controlled trial have shown that both treatment were effective on overall symptomatology but the onset of action of CI + PL was more rapid than CI + P.
D000328:Adult; D000368:Aged; D002997:Clomipramine / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D008081:Liposomes; D010743:Phospholipids; D002997:Clomipramine